Article Details
Retrieved on: 2018-02-08 00:07:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Nessan Bermingham, the founding CEO of CRISPR drug maker Intellia Therapeutics (NASDAQ: NTLA), is returning to <b>Atlas Venture</b> as a venture partner. Bermingham led Intellia from its incubation in the Cambridge, MA, venture capital firm through its 2016 initial public stock offering. Bermingham first ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here